

Beth Williamson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2037000/publications.pdf>

Version: 2024-02-01

13
papers

289
citations

1163117

8
h-index

1281871

11
g-index

13
all docs

13
docs citations

13
times ranked

327
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessment. Archives of Toxicology, 2022, 96, 613-624.	4.2	6
2	Prediction of In Vivo Pharmacokinetic Parameters and Time-Exposure Curves in Rats Using Machine Learning from the Chemical Structure. Molecular Pharmaceutics, 2022, 19, 1488-1504.	4.6	23
3	Identification and Strategies to Mitigate High Total Clearance of Benzylamine-Substituted Biphenyl Ring Systems. Molecular Pharmaceutics, 2022, , .	4.6	0
4	Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK. ACS Medicinal Chemistry Letters, 2022, 13, 1295-1301.	2.8	0
5	A Novel Method for Preventing Non-specific Binding in Equilibrium Dialysis Assays Using Solutol [®] as an Additive. Journal of Pharmaceutical Sciences, 2021, 110, 1412-1417.	3.3	6
6	Blood retinal barrier and ocular pharmacokinetics: Considerations for the development of oncology drugs. Biopharmaceutics and Drug Disposition, 2021, 42, 128-136.	1.9	5
7	Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase. Bioorganic and Medicinal Chemistry Letters, 2021, 39, 127904.	2.2	10
8	Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy. Journal of Medicinal Chemistry, 2021, 64, 13524-13539.	6.4	13
9	Machine Learning Models for Human In Vivo Pharmacokinetic Parameters with In-House Validation. Molecular Pharmaceutics, 2021, 18, 4520-4530.	4.6	37
10	The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 3461-3471.	6.4	47
11	Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discovery Today, 2020, 25, 1793-1800.	6.4	108
12	Evaluation of the Disconnect between Hepatocyte and Microsome Intrinsic Clearance and In Vitro In Vivo Extrapolation Performance. Drug Metabolism and Disposition, 2020, 48, 1137-1146.	3.3	25
13	Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy. Current Drug Metabolism, 2020, 21, 145-162.	1.2	9